Table 3.

The studies evaluating the role of neutrophil to lymphocyte of urothelial cancer pathologic staging.

Study	Year	Cases	Stage	Assessment and treatment	Threshold	Predictable variable	Outcomes
Can et al. (69)	2012	182	pT0-4N0M0	Pre-TURBT	2.57	MIBC possibility	OR 2.78 (1.38–5.59), P = 0.004
Lee et al. (70)	2015	226	pT0-4N0M0	Pre-TURBT	3.89	MIBC possibility	OR 8.24 (2.49–27.32), P = 0.001
Krane et al. (49)	2013	68	Recurrent T1 + MIBC	Pre-RC	2.5	Extravesical disease	OR 3.18 (1.09–9.79)
Potretzke et al. (71)	2014	102	pT0-4N0M0	Pre-RC	Continuous	≥pT3 upstaging Extravesical disease	OR 1.36 (1.01–1.84), P = 0.040 OR 1.5 (1.07–2.10), P = 0.020
Viers et al. (48)	2014	889	pT0-4N0M0	Pre-RC	2.7	Extravesical disease LN involvement	OR 1.07 (1.01–1.15), P = 0.030 OR 1.09 (1.02–1.16), P = 0.020
Buisan et al. (58)	2016	205	pT0-4Nx-2M0	Pre-RC	Continuous	pCR	OR 0.80 (0.64–0.99), P = 0.04
D'Andrea et al. (41)	2017	4435	pT0-4N0M0	Pre-RC	2.7	LN involvement	OR 1.9 (1.7–2.3), P < 0.001
Seah et al. (72)	2015	26	pT0-4N0-3	Pre-NAC/Mid/Pre-RC	Kinetics	NLR pattern during NAC	Different between pCR and non-responder, P = 0.038
Leibowitz-Amit et al. (73)	2016	55	pT2-4N0M0	Pre-NAC	Continuous	pCR	OR 0.48 (0.23–0.98), P = 0.05

LN, lymph node; NLR, neutrophil to lymphocyte ratio; MIBC, muscle invasive bladder cancer; OR, odd ratio; OS, overall survival; pCR, pathologic complete response; RC, radical cystectomy; TURBT, transurethral resection of bladder tumor.